#Canada #Quebec City #Devonian Health Group #Thykamine™ #radiodermatitis

Devonian Health Group Launches Clinical Study for Thykamine™

Devonian Health Group Inc., a biopharmaceutical company focused on developing botanical therapeutics for inflammatory diseases, has announced a significant advancement in its clinical program. The company has received Health Canada authorization for a clinical trial aimed at evaluating a new formulation of Thykamine™, a proprietary compound intended to prevent radiation-induced skin injuries in breast cancer patients undergoing radiotherapy.

Key Highlights of the Initiative

The clinical trial will involve 150 participants in a randomized, double-blind, multicenter format. The primary objective of the study is to assess the efficacy of the Thykamine™ 0.1% formulation compared to the standard Glaxal Base cream in preventing Grade 2 or higher radiodermatitis—a prevalent skin condition affecting patients receiving radiation therapy. This initiative marks the company's expansion into supportive oncology, addressing a critical medical need.

Addressing a Significant Challenge in Oncology

Radiodermatitis, or radiation-induced dermatitis, can affect up to 95% of patients treated with external beam radiation, particularly those undergoing treatment for breast cancer. This condition can lead to various symptoms, including erythema, dryness, and painful ulceration that disrupt the patients' quality of life and potentially their treatment continuity.

Despite advancements in radiotherapy techniques and skin care products, effective preventive strategies for radiodermatitis remain limited. A recent systematic review by the Multinational Association of Supportive Care in Cancer highlights the need for more evidence-backed interventions, emphasizing the impact of this condition on patients' health and well-being.

The Promise of Thykamine™

Devonian's new formulation of Thykamine™, built upon prior scientific research, is designed with unique properties expected to modulate oxidative stress and inflammation—key mechanisms involved in the development of radiodermatitis. Preliminary preclinical findings have demonstrated its potential efficacy, suggesting that this formulation could significantly alleviate the repercussions of radiation exposure on the skin.

Clinical Study Overview

Study Design

• - Participants: 150 adult female patients undergoing radiotherapy for breast cancer
• - Trial Type: Randomized, double-blind, multicenter, parallel-group controlled study
• - Treatment Groups: Comparison of Thykamine™ 0.1% formulation versus Glaxal Base cream
• - Regimen: Topical application three times daily during radiotherapy, extending five weeks post-treatment
• - Duration: Approximately eight to nine weeks per participant

Evaluation Metrics

The primary endpoint focuses on the time until the onset of Grade 2 or higher radiodermatitis determined by standardized clinical criteria. Secondary endpoints will include the rate of radiodermatitis, measurement of patient-reported pain, and overall satisfaction along with monitoring for any adverse events during the study period.

Shaping Future Health Outcomes

Through the execution of this clinical trial, Devonian aims not only to refine a therapeutic option to mitigate the effects of radiodermatitis but also to open avenues for discussing regulatory strategy. The company is considering a medical-device pathway for the Thykamine™ formulation, which may lead to a more efficient development and commercialization process compared to traditional pharmaceutical routes.

Management Insights

Dr. André P. Boulet, CEO of Devonian, expressed optimism regarding this authorization from Health Canada, recognizing it as a crucial milestone in the company's mission to enhance patient care in the oncology space. He affirmed the intention to tackle ongoing challenges in radiodermatitis and the potential for this formulation to aid patients significantly.

Next Steps

Following this substantial authorization, Devonian is set to initiate operational preparations for the study, which will include site activations and participant recruitment. As the project progresses, the company will provide updates related to the trial's success and developments.

This new research not only highlights the pressing need for solutions within supportive oncology but also illustrates Devonian Health Group's commitment to advancing therapeutic options that address significant unmet medical needs in cancer care.